Clinical trials: Solid Malignant Tumor
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
This phase I trial is studying the side effects and best dose of vorinostat in treating patients with metastatic or unresectable solid tumors or lymphoma and liver dysfunction.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00499811
- Testing
- vorinostat, pharmacological study
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer, Solid Tumor
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT03080311
- Testing
- APG-1252
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascentage Pharma Group Inc.
Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes.
- Conditions
- Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03735095
- Testing
- Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Solid Tumor, Hematologic Malignancies
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
The primary objective of this study is to establish the feasibility and value of physical fitness assessment within patients receiving cytotoxic chemotherapy.
- Trial name
- NCT02844400
- Testing
- Biometric Devices, Physical Performance Testing
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chemotherapy-induced Symptomatic Anemia, Solid Tumors
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
- Conditions
- Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas
- Trial name
- ORHEO (NCT02140736)
- Testing
- Epoetin biosimilar
- Where
- 172 sites in France
- Volunteers
- 2,333 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Neoplasms, Lymphoma
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
Background: The experimental drug IPdR is broken down in the body to IdUrd, which has been given to patients to find out if it can improve radiation therapy.
- Trial name
- NCT01240577
- Testing
- IPdR
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
HER2 or EGFR Expressing Advanced Solid Malignancies
MAD Refractory: Solid Tumor QD w/o Break
This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
- Trial name
- NCT00207012
- Testing
- BMS-599626
- Where
- 2 sites in France, Spain
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1 study of RO6927005. The study will establish the safety and tolerability profile of RO6927005 and will be conducted in two parts.
- Trial name
- NCT02317419
- Testing
- RO6927005, gemcitabine, nab-paclitaxel
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers
The rationale for conducting this study lies in the premise that if indeed the reason for a limited response of Kaposi's sarcoma lesions and other advanced malignancies to chemotherapy is attributable to a high expression of…
- Trial name
- NCT00003207
- Testing
- pegylated liposomal doxorubicin hydrochloride, PSC 833
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Washington University School of Medicine
Malignant Solid Tumour
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, dose-escalation trial in patients with advanced solid tumors. The trial comprises 2 stages: a dose escalation stage at 8 dose levels of 2, 5, 10, 20, 40, 60, 80, and 100 mg/day,and possibly…
- Trial name
- NCT01184807
- Testing
- OPB-51602
- Where
- 2 sites in Singapore
- Volunteers
- 51 people
- Sponsor
- Otsuka Beijing Research Institute
Advanced Solid Tumor
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with…
- Trial name
- NCT05075564
- Testing
- Part 1 ES002023, Part 2 ES002023
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Elpiscience Biopharma, Ltd.
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
HER2-Positive Solid Tumors
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
This is a non-randomized, open-label, single-arm, multicenter Phase I clinical trial which will evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody in…
- Trial name
- NCT04280341
- Testing
- RC48-ADC in combinaton with JS001
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Testing the Safety of CB-5339 in Patients With Cancer
This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04372641
- Testing
- p97 Inhibitor CB-5339 Tosylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Locally Advanced Malignant Solid Neoplasm
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
This phase II trial studies how well pembrolizumab works before surgery in treating patients with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes (locally advanced).
- Trial name
- NCT04082572
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Neoplasms
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
Background: SNX-5422 is an experimental drug that inhibits a protein called Hsp90, which is important for the growth of tumor cells. SNX-5422 has shown some activity against tumors in the laboratory and animal studies.
- Trial name
- NCT00644072
- Testing
- SNX-5422
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: UCN-01 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00045500
- Testing
- 7-hydroxystaurosporine, prednisone
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.
- Trial name
- NCT03364400
- Testing
- VT1021
- Where
- 12 sites in United States
- Volunteers
- 116 people
- Sponsor
- Vigeo Therapeutics, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.